| Name | Title | Contact Details |
|---|---|---|
Charles Marra |
Vice President of Technology | Profile |
Nick Gianadda |
Chief Technology Officer | Profile |
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
Alergan is a Waco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.